Table 1.
Current clinical presentation and management of Hodgkin lymphoma
| Histology | Incidence (%) | Age at diagnosis | Clinical characteristics | Treatment | Outcome, PFS (%) |
|---|---|---|---|---|---|
| cHL | 95 | Bimodal | |||
| NSCHL | 70 | Young adults (10 to 30 years) | Frequent mediastinal involvement | ABVD±RT | 80 |
| MCCHL | 10 to 25 | Bimodal distribution, 3rd to 7th decade | Infrequent mediastinal involvement | ABVD±RT | <80 |
| LDCHL | 1 | Bimodal distribution, 3rd to 7th decade | Infrequent mediastinal involvement | ABVD±RT | <80 |
| LRCHL | 1 | Bimodal distribution, 3rd to 7th decade | Infrequent mediastinal involvement | ABVD±RT | >90 |
| NLPHL | 5 | 4th decade | Infrequent mediastinal involvement | ABVD±RT, rituximab | Good prognosis, multiple relapses |
ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; cHL, classical Hodgkin lymphoma; LDCHL, lymphocyte-depletion classical Hodgkin lymphoma; LRCHL, lymphocyte-rich classical Hodgkin lymphoma; MCCHL, mixed-cellularity classical Hodgkin lymphoma; NLPHL, nodular lymphocyte-predominant Hodgkin lymphoma; NSCHL, nodular-sclerosis classical Hodgkin lymphoma; PFS, progression-free survival; RT, radiotherapy.